Oncological practices in the clinical management of breast cancer: An Indian survey

26^th World Cancer and Oncodiagnostics Conference

November 27-28, 2017 Dubai, UAE

Ashish Bajaj, Ramez Ahmed and Dilip Pawar

Biocon Limited, India

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Aim: A survey was conducted to understand clinical practices in the management of breast cancer in Indian patients. Materials & Methods: A questionnaire was developed to undertake a survey among oncologists across India in 2016. Response from 17 doctors were recorded and analyzed. Results: Around 35.41% newly diagnosed cases, 37.53% follow-up patients and 24.12% relapsed breast cancer patients are treated by these doctors. Around 52.9% patients were of early breast cancer (EBC) and 47.1% were metastatic breast cancer (MBC). For first line therapy for HER2 positive EBC, 35.3% prefer targeted therapy, 17.6% use Trastuzumab as choice of targeted therapy and for HER2 positive MBC, 11.8% prefer targeted therapy with hormonal therapy, 11.8% use only targeted therapy and 11.8% use trastuzumab as choice of targeted therapy. For second line therapy for HER2 positive EBC, 11.8% use targeted therapy, 11.8% use targeted therapy with hormonal therapy, 11.8% use lapatinib and for HER2 positive MBC, 29.4% use Trastuzumab Emtansine (TDM1), 11.8% use targeted therapy, 11.8% use trastuzumab as choice of targeted therapy. Trastuzumab as choice of anti-HER2 agent was used in 94.1% doctors, 88.2% use lapatinib, 64.7% use Pertuzumab and 58.8% use TDM1. Conclusion: Trastuzumab stands out as choice of targeted therapy as an anti-HER2 agent for early and metastatic breast cancer in clinical practice as reiterated in this survey with Indian oncologists.

Biography :

Ashish Bajaj has completed his MD in Pharmacology and presently is a Medical Advisor in Oncology at Biocon Limited.